|
Loading...
| ||||||||||||||
Recent Publications by Pfizer Global Research and Development: |  | |
| Sequence Analysis of the IL28A/IL28B Inverted Gene Duplication That Contains Polymorphisms Associated with Treatment Response in Hepatitis C Patients.
Several SNPs located in or around the IL28B gene are associated with... | DNA and BioFluids Research Center of Emphasis, Pfizer Global Research and | PLoS One. 2012;7(1):e29983. Epub 2012 Jan 10.
DOI Direct Link |
| Age-dependent disruption in hippocampal theta oscillation in amyloid-beta overproducing transgenic mice.
Transgenic mice are used to model increased brain amyloid-beta (Abeta) and... | Pfizer Global Research and Development, Groton, CT, USA. | Neurobiol Aging. 2012 Jan 6.
DOI Direct Link |
| Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events.
Positive allosteric modulators ('potentiators') of the... | Department of Pharmacokinetics, Pharmacodynamics and Metabolism, Pfizer | Biopharm Drug Dispos. 2011 Dec 28. doi: 10.1002/bdd.1768.
DOI Direct Link |
| In vitro characterization of the activity of PF-05095808 a novel biological agent for Hepatitis C Virus therapy.
PF-05095808 is a novel biological agent for chronic Hepatitis C Virus... | Pfizer Global Research and Development, Sandwich, Kent, CT13 9NJ, UK. | Antimicrob Agents Chemother. 2011 Dec 27.
DOI Direct Link |
| Report on stage III Pig-a mutation assays using N-ethyl-N-nitrosourea-comparison with other in vivo genotoxicity endpoints.
N-Ethyl-N-nitrosourea (ENU) was evaluated as part of the Stage III trial... | Pfizer Global Research and Development, Genetic Toxicology Center of | Environ Mol Mutagen. 2011 Dec;52(9):721-30. |